Dafinchi AI

QGEN

Healthcare

Adjusted diluted EPS was $0.60 ($0.62 at CER), exceeding guidance due to improved operational profitability.
Adjusted operating income margin rose to 29.9% of sales, up 1.5 percentage points from Q2 2024, driven by efficiency initiatives and cost discipline.
Core sales, excluding discontinued products NeuMoDx and DIALUNOX, grew 6% CER.
Free cash flow was $270 million in H1 2025, slightly below $225 million in H1 2024 due to higher planned investments in digital initiatives.
Net cash from operating activities was $301 million in H1 2025, stable compared to H1 2024, despite $36 million cash restructuring payments.
QGEN reported net sales of $534 million in Q2 2025, a 7% increase year-over-year and 6% growth at constant exchange rates (CER).
Regional sales: Americas +7% CER, EMEA +8% CER, Asia Pacific declined 4% CER with China down in low teens.
Sales growth was strong in diagnostic solutions (+11% CER), led by QIAstat-DX (+41% CER) and QuantiFERON (+11% CER).
Sample technologies sales were flat year-over-year, with mid-single-digit growth in automated consumables.

AMRX

Healthcare

Reported Q2 revenues of $720 million and adjusted EBITDA of $184 million, with confidence in raising 2025 guidance.
Emphasized diversified portfolio and multiple growth drivers including new product launches, complex medicines, biosimilars, and strategic partnerships.
Projected continued growth with a focus on innovative and affordable medicines, aiming to be America's #1 affordable medicines company.

Earnings Feed